This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chikamatsu, K. Articles by DeLeo, A. B. Search for Related Content PubMed PubMed Citation Articles by Chikamatsu, K. Articles by DeLeo, A. B.

p53_110–124-specific Human CD4⁺ T-helper Cells Enhance in Vitro Generation and Antitumor Function of Tumor-reactive CD8⁺ T Cells¹

Division of Basic Research, University of Pittsburgh Cancer Institute and the Departments of Pathology [K. C., A. A., J. S., T. L. W., A. B. D.] and Otolaryngology [T. L. W.], School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15213; Virginia Mason Research Institute and University of Washington School of Medicine, Seattle, Washington 98101 [W. W. K.] and National Cancer Institute, Bethesda, Maryland 20892 [E. A.]

Current evidence suggests that the optimal vaccines for cancer should incorporate tumor-specific cytotoxic as well as helper epitopes. Wild-type sequence (wt) p53 peptides are attractive candidates for broadly applicable cancer vaccines, which could combine multiple tumor epitopes defined by CD8⁺ CTLs, as well as CD4⁺ T-helper cells. To test this possibility, we generated anti-p53 CD4⁺ T cells from peripheral blood obtained from an HLA-DRB1*0401⁺ donor by in vitro stimulation with dendritic cells and recombinant human p53 protein. We identified the wt p53_110–124 peptide as a naturally presented epitope. In a series of ex vivo experiments, performed in an autologous human system, we then demonstrated the ability of anti-wt p53_110–124 CD4⁺ T cells to enhance the generation and antitumor functions of CD8⁺ effector cells. The results demonstrate the crucial role of T helper-defined epitopes in shaping the immune response to multiepitope cancer vaccines targeting p53. This model of tumor-specific CD8⁺ and CD4⁺ T-cell interactions suggests that future vaccination strategies targeting tumor cells should incorporate helper and cytotoxic T cell-defined epitopes.

This article has been cited by other articles:

				M. M. Lauwen, S. Zwaveling, L. de Quartel, S. C. Ferreira Mota, J. A.C. Grashorn, C. J.M. Melief, S. H. van der Burg, and R. Offringa Self-Tolerance Does Not Restrict the CD4+ T-Helper Response against the p53 Tumor Antigen Cancer Res., February 1, 2008; 68(3): 893 - 900. [Abstract] [Full Text] [PDF]

				M. E. Couch, R. L. Ferris, J. A. Brennan, W. M. Koch, E. M. Jaffee, M. S. Leibowitz, G. T. Nepom, H. A. Erlich, and D. Sidransky Alteration of Cellular and Humoral Immunity by Mutant p53 Protein and Processed Mutant Peptide in Head and Neck Cancer Clin. Cancer Res., December 1, 2007; 13(23): 7199 - 7206. [Abstract] [Full Text] [PDF]

				C. Visus, D. Ito, A. Amoscato, M. Maciejewska-Franczak, A. Abdelsalem, R. Dhir, D. M. Shin, V. S. Donnenberg, T. L. Whiteside, and A. B. DeLeo Identification of Human Aldehyde Dehydrogenase 1 Family Member A1 as a Novel CD8+ T-Cell Defined Tumor Antigen in Squamous Cell Carcinoma of the Head and Neck Cancer Res., November 1, 2007; 67(21): 10538 - 10545. [Abstract] [Full Text] [PDF]

				L. Strauss, C. Bergmann, W. Gooding, J. T. Johnson, and T. L. Whiteside The Frequency and Suppressor Function of CD4+CD25highFoxp3+ T Cells in the Circulation of Patients with Squamous Cell Carcinoma of the Head and Neck Clin. Cancer Res., November 1, 2007; 13(21): 6301 - 6311. [Abstract] [Full Text] [PDF]

				D. Ito, A. Albers, Y. X. Zhao, C. Visus, E. Appella, T. L. Whiteside, and A. B. DeLeo The Wild-Type Sequence (wt) p5325-35 Peptide Induces HLA-DR7 and HLA-DR11-Restricted CD4+ Th Cells Capable of Enhancing the Ex Vivo Expansion and Function of Anti-wt p53264-272 Peptide CD8+ T Cells J. Immunol., November 15, 2006; 177(10): 6795 - 6803. [Abstract] [Full Text] [PDF]

				R. L. Ferris, T. L. Whiteside, and S. Ferrone Immune Escape Associated with Functional Defects in Antigen-Processing Machinery in Head and Neck Cancer. Clin. Cancer Res., July 1, 2006; 12(13): 3890 - 3895. [Abstract] [Full Text] [PDF]

				C. Badoual, S. Hans, J. Rodriguez, S. Peyrard, C. Klein, N. E. H. Agueznay, V. Mosseri, O. Laccourreye, P. Bruneval, W. H. Fridman, et al. Prognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck Cancers Clin. Cancer Res., January 15, 2006; 12(2): 465 - 472. [Abstract] [Full Text] [PDF]

				B. Wu, A. Ootani, R. Iwakiri, Y. Sakata, T. Fujise, S. Amemori, F. Yokoyama, S. Tsunada, S. Toda, and K. Fujimoto T Cell Deficiency Leads to Liver Carcinogenesis in Azoxymethane-Treated Rats Experimental Biology and Medicine, January 1, 2006; 231(1): 91 - 98. [Abstract] [Full Text] [PDF]

				C. J. Cohen, Z. Zheng, R. Bray, Y. Zhao, L. A. Sherman, S. A. Rosenberg, and R. A. Morgan Recognition of Fresh Human Tumor by Human Peripheral Blood Lymphocytes Transduced with a Bicistronic Retroviral Vector Encoding a Murine Anti-p53 TCR J. Immunol., November 1, 2005; 175(9): 5799 - 5808. [Abstract] [Full Text] [PDF]

				C. Mayr, D. M. Kofler, H. Buning, D. Bund, M. Hallek, and C.-M. Wendtner Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells Blood, November 1, 2005; 106(9): 3223 - 3226. [Abstract] [Full Text] [PDF]

				N. A. Danke, D. M. Koelle, C. Yee, S. Beheray, and W. W. Kwok Autoreactive T Cells in Healthy Individuals J. Immunol., May 15, 2004; 172(10): 5967 - 5972. [Abstract] [Full Text] [PDF]

				M. Ruiz, H. Kobayashi, J. J. Lasarte, J. Prieto, F. Borras-Cuesta, E. Celis, and P. Sarobe Identification and Characterization of a T-Helper Peptide from Carcinoembryonic Antigen Clin. Cancer Res., April 15, 2004; 10(8): 2860 - 2867. [Abstract] [Full Text] [PDF]